Global Cephalosporin Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2016-2027
- Published Date: 2021-04-23
- Report ID: 104763
- Pages: 129
-
Format:
Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Prudent Markets published a report for global Cephalosporin market in this environment.
In terms of revenue, this research report indicated that the global Cephalosporin market was valued at USD XXX million in 2020, and it is expected to reach a value of USD XXX million by 2027, at a CAGR of XX % over the forecast period 2021-2027. Correspondingly, the forecast analysis of Cephalosporin industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Union Chempharma aims at producing XX K Units Cephalosporin in 2020, with XX % production to take place in global market, NCPC accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2026-2027) of Cephalosporin Market by Prudent Markets Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Cephalosporin Market
Union Chempharma
NCPC
Qilu Antibiotics
Lupin Pharmaceuticals
Hospira
Dhanuka Laboratories
Fukang
Dongying Pharmaceutical
Alkem
SALUBRIS
LIVZON
Hetero Drugs
CSPC
TEVA
Orchid Pharma
Taj Pharmaceuticals
Covalent Laboratories
United Laboratories
Aurobindo
Wockhardt
LKPC
HPGC
Huafangpharm
...
Major Type of Cephalosporin Covered in Prudent Markets report:
First Generation
Second Generation
Third Generation
Fourth Generation
Application Segments Covered in Prudent Markets Market
Oral
Injection
Application 3
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global Cephalosporin Market Analysis 2021, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 First Generation -Product Introduction and Major Manufacturers
1.1.2 Second Generation -Product Introduction and Major Manufacturers
1.1.3 Third Generation -Product Introduction and Major Manufacturers
1.1.4 Fourth Generation -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Cephalosporin Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2026-2027)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2026-2027)
2.3 Application Breakdown Estimates & Forecast, by Application (2026-2027)
3 Regional Market Analysis
3.1 China Cephalosporin Market
3.1.1 Top Companies leading Cephalosporin Development in China (2016-2021)
3.1.2 Sales Value of Major Company in China Market (2016-2021)
3.1.3 China Cephalosporin Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2026-2027)
3.2 EU Cephalosporin Market
3.2.1 Top Companies leading Cephalosporin Development in EU (2016-2021)
3.2.2 Sales Value of Major Company in EU Market (2016-2021)
3.2.3 EU Cephalosporin Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2026-2027)
3.3 USA Cephalosporin Market
3.3.1 Top Companies leading Cephalosporin Development in USA (2016-2021)
3.3.2 Sales Value of Major Company in USA Market (2016-2021)
3.3.3 USA Cephalosporin Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2026-2027)
3.4 Japan Cephalosporin Market
3.4.1 Top Companies leading Cephalosporin Development in Japan (2016-2021)
3.4.2 Sales Value of Major Company in Japan Market (2016-2021)
3.4.3 Japan Cephalosporin Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2026-2027)
3.5 India Cephalosporin Market
3.5.1 Top Companies leading Cephalosporin Development in India (2016-2021)
3.5.2 Sales Value of Major Company in India Market (2016-2021)
3.5.3 India Cephalosporin Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2026-2027)
3.6 Southeast Asia Cephalosporin Market
3.6.1 Top Companies leading Cephalosporin Development in Southeast Asia (2016-2021)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2016-2021)
3.6.3 Southeast Asia Cephalosporin Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2026-2027)
3.7 South America Cephalosporin Market
3.7.1 Top Companies leading Cephalosporin Development in South America (2016-2021)
3.7.2 Sales Value of Major Company in South America Market (2016-2021)
3.7.3 South America Cephalosporin Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2026-2027)
4 Value Chain (Impact of COVID-19)
4.1 Cephalosporin Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on Cephalosporin Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2027)
5.1 Global Cephalosporin Sales and Growth Rate (2021-2027)
5.2 Global Cephalosporin Sales Value and Growth Rate (2021-2027)
6 Cephalosporin Competitive Analysis
6.1 Union Chempharma
6.1.1 Union Chempharma Company Profiles
6.1.2 Union Chempharma Product Introduction
6.1.3 Union Chempharma Cephalosporin Production, Revenue (2016-2021)
6.1.4 SWOT Analysis
6.2 NCPC
6.2.1 NCPC Company Profiles
6.2.2 NCPC Product Introduction
6.2.3 NCPC Cephalosporin Production, Revenue (2016-2021)
6.2.4 SWOT Analysis
6.3 Qilu Antibiotics
6.3.1 Qilu Antibiotics Company Profiles
6.3.2 Qilu Antibiotics Product Introduction
6.3.3 Qilu Antibiotics Cephalosporin Production, Revenue (2016-2021)
6.3.4 SWOT Analysis
6.4 Lupin Pharmaceuticals
6.4.1 Lupin Pharmaceuticals Company Profiles
6.4.2 Lupin Pharmaceuticals Product Introduction
6.4.3 Lupin Pharmaceuticals Cephalosporin Production, Revenue (2016-2021)
6.4.4 SWOT Analysis
6.5 Hospira
6.5.1 Hospira Company Profiles
6.5.2 Hospira Product Introduction
6.5.3 Hospira Cephalosporin Production, Revenue (2016-2021)
6.5.4 SWOT Analysis
6.6 Dhanuka Laboratories
6.6.1 Dhanuka Laboratories Company Profiles
6.6.2 Dhanuka Laboratories Product Introduction
6.6.3 Dhanuka Laboratories Cephalosporin Production, Revenue (2016-2021)
6.6.4 SWOT Analysis
6.7 Fukang
6.7.1 Fukang Company Profiles
6.7.2 Fukang Product Introduction
6.7.3 Fukang Cephalosporin Production, Revenue (2016-2021)
6.7.4 SWOT Analysis
6.8 Dongying Pharmaceutical
6.8.1 Dongying Pharmaceutical Company Profiles
6.8.2 Dongying Pharmaceutical Product Introduction
6.8.3 Dongying Pharmaceutical Cephalosporin Production, Revenue (2016-2021)
6.8.4 SWOT Analysis
6.9 Alkem
6.9.1 Alkem Company Profiles
6.9.2 Alkem Product Introduction
6.9.3 Alkem Cephalosporin Production, Revenue (2016-2021)
6.9.4 SWOT Analysis
6.10 SALUBRIS
6.10.1 SALUBRIS Company Profiles
6.10.2 SALUBRIS Product Introduction
6.10.3 SALUBRIS Cephalosporin Production, Revenue (2016-2021)
6.10.4 SWOT Analysis
6.11 LIVZON
6.12 Hetero Drugs
6.13 CSPC
6.14 TEVA
6.15 Orchid Pharma
6.16 Taj Pharmaceuticals
6.17 Covalent Laboratories
6.18 United Laboratories
6.19 Aurobindo
6.20 Wockhardt
6.21 LKPC
6.22 HPGC
6.23 Huafangpharm
7 Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
